Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary E Sander

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Current Treatment Options in Cardiovascular Medicine|February 23, 2002
Cardiovascular Complications of Collagen Vascular DiseaseGary E. Sander, Thomas D. Giles
Journal of Clinical Hypertension (Greenwich, Conn.)|November 10, 2005
Pathophysiologic, diagnostic, and therapeutic aspects of the metabolic syndromeThomas D Giles, Gary E Sander
Future Cardiology|October 16, 2020
Nebivolol/valsartan combination for the treatment of hypertension: a reviewSarah J Wang, Gary E Sander
The American Journal of Geriatric Cardiology|July 20, 2006
The endocannabinoid system and cardiovascular risk: pathophysiologic role and developing therapeutic interventionsGary E Sander, Thomas D Giles
Expert Opinion on Pharmacotherapy|March 10, 2015
Nebivolol and valsartan as a fixed-dose combination for the treatment of hypertensionGary E Sander, Thomas D Giles
The American Journal of Geriatric Cardiology|July 15, 2005
Medical management of myocardial ischemiaGary E Sander, Thomas D Giles
Current Hypertension Reports|August 10, 2007
Effects of thiazolidinediones on blood pressureThomas D Giles, Gary E Sander
Journal of Clinical Hypertension (Greenwich, Conn.)|August 19, 2014
Vascular stiffness is a biomarker of global cardiovascular riskGary E Sander, Thomas D Giles
The American Journal of Geriatric Cardiology|July 23, 2004
Ximelagatran: light at the end of the tunnel or the next tunnel?Gary E Sander, Thomas D Giles
The American Journal of Geriatric Cardiology|May 12, 2005
Alcohol--a cardiovascular drug?Thomas D Giles, Gary E Sander
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Current Treatment Options in Cardiovascular Medicine|February 23, 2002
Cardiovascular Complications of Collagen Vascular DiseaseGary E. Sander, Thomas D. Giles
Journal of Clinical Hypertension (Greenwich, Conn.)|November 10, 2005
Pathophysiologic, diagnostic, and therapeutic aspects of the metabolic syndromeThomas D Giles, Gary E Sander
Future Cardiology|October 16, 2020
Nebivolol/valsartan combination for the treatment of hypertension: a reviewSarah J Wang, Gary E Sander
The American Journal of Geriatric Cardiology|July 20, 2006
The endocannabinoid system and cardiovascular risk: pathophysiologic role and developing therapeutic interventionsGary E Sander, Thomas D Giles
Expert Opinion on Pharmacotherapy|March 10, 2015
Nebivolol and valsartan as a fixed-dose combination for the treatment of hypertensionGary E Sander, Thomas D Giles
The American Journal of Geriatric Cardiology|July 15, 2005
Medical management of myocardial ischemiaGary E Sander, Thomas D Giles
Current Hypertension Reports|August 10, 2007
Effects of thiazolidinediones on blood pressureThomas D Giles, Gary E Sander
Journal of Clinical Hypertension (Greenwich, Conn.)|August 19, 2014
Vascular stiffness is a biomarker of global cardiovascular riskGary E Sander, Thomas D Giles
The American Journal of Geriatric Cardiology|July 23, 2004
Ximelagatran: light at the end of the tunnel or the next tunnel?Gary E Sander, Thomas D Giles
The American Journal of Geriatric Cardiology|May 12, 2005
Alcohol--a cardiovascular drug?Thomas D Giles, Gary E Sander
Pageof 4